At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 22, 2026 at 16:04 ET
Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the re-election of eight directors, approval of executive compensation, and reappointment of its auditor. This routine filing follows a recent amendment to its equity incentive plan, indicating ongoing governance activities.
- Filing is a definitive proxy statement (DEFA14A) for the 2025 annual meeting
- Proposes re-election of eight directors including Dawn Svoronos, Gillian Cannon, and Justin Gover
- Seeks approval of executive compensation and reappointment of PwC as auditor
- Follows recent 8-K filing amending the equity incentive plan
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access